利用脑髓母细胞瘤的克隆动力学来克服治疗阻力
David Bakhshinyan1,2, Stefan Custers1,3, Laura Escudero1,3
1McMaster Centre for Discovery in Cancer Research, McMaster University, Hamilton, Canada.
概括
用PTC596针对BMI1显示出对3组脑髓母细胞瘤的前景. 将BMI1抑制与PI3K通路向相结合,提供了一种协同方法来改善患者的生存率和持久的缓解.
科学领域:
- 在瘤学瘤学.
- 儿科神经瘤学 儿科神经瘤学
- 分子生物学分子生物学
背景情况:
- 第三组髓母细胞瘤是一种具有不良结果的侵袭性儿科脑瘤.
- 特定于B细胞的Moloney小鼠白血病病毒插入部位1 (BMI1) 抑制剂显示有效性,但单独不足.
- 之前的研究已经确定了BMI1抑制作为脑髓母细胞瘤的治疗策略.
研究的目的:
- 在BMI1抑制下研究3组髓母细胞瘤的体内克隆动态.
- 为了确定治疗不耐药的脑髓母细胞瘤的新型治疗漏洞.
- 探索与BMI1抑制剂PTC596.6的协同作用组合.
主要方法:
- 对BMI1抑制剂PTC596.6的临床前验证
- 用DNA条形码来描述体内克隆动态.
- 蛋白质分析和全基因组CRISPR查以确定漏洞.
- 针对PI3K等已识别的途径进行向.
主要成果:
- 在3组脑髓母细胞瘤中证明了耐治疗的克隆.
- 确定了mTOR,AKT和PLK1通路的特定环境调节剂.
- 协同向PI3K通路与酶氨酸以及BMI1抑制是最有效的.
结论:
- 与PI3K通路向相结合的BMI1抑制提供了一个有希望的策略.
- 这种方法可以改善耐药性脑髓母细胞瘤患者的缓解耐久性和生存率.
- 为协同作用抑制剂的临床验证奠定了基础.
相关概念视频
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Cancer Stem Cells and Tumor Maintenance
5.9K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.9K
Adaptive Mechanisms in Cancer Cells
6.9K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.9K


